This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comparative Study

. 2005 Mar;2(3):126-7.

doi: 10.1038/ncponc0110.

Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?

Affiliations

PMID: 16264901
DOI: 10.1038/ncponc0110

Comparative Study

Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?

John Goldman. Nat Clin Pract Oncol. 2005 Mar.

. 2005 Mar;2(3):126-7.

doi: 10.1038/ncponc0110.

Author

Affiliation

¹ Department of Hematology, Imperial College at Hammersmith Hospital, London, UK. goldmanj2@nhlbi.nih.gov

PMID: 16264901
DOI: 10.1038/ncponc0110

No abstract available

PubMed Disclaimer

Similar articles

Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA. Reed SD, et al. Cancer. 2004 Dec 1;101(11):2574-83. doi: 10.1002/cncr.20694. Cancer. 2004. PMID: 15493042
Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E, Ward S, Gordois A, Scuffham P. Warren E, et al. Clin Ther. 2004 Nov;26(11):1924-33. doi: 10.1016/j.clinthera.2004.11.007. Clin Ther. 2004. PMID: 15639704
Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP).
Chen Z, Wang C, Xu X, Feng W. Chen Z, et al. Value Health. 2009 Nov-Dec;12 Suppl 3:S85-8. doi: 10.1111/j.1524-4733.2009.00635.x. Value Health. 2009. PMID: 20586990
Imatinib mesylate--a new oral targeted therapy.
Savage DG, Antman KH. Savage DG, et al. N Engl J Med. 2002 Feb 28;346(9):683-93. doi: 10.1056/NEJMra013339. N Engl J Med. 2002. PMID: 11870247 Review. No abstract available.
The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
Garside R, Round A, Dalziel K, Stein K, Royle P. Garside R, et al. Health Technol Assess. 2002;6(33):1-162. doi: 10.3310/hta6330. Health Technol Assess. 2002. PMID: 12633529 No abstract available.

See all similar articles

Cited by

Imatinib-Induced Bone Marrow Aplasia in Chronic Myelogenous Leukemia.
Dogra R, Dogra V, Shelke AR. Dogra R, et al. Cureus. 2024 May 27;16(5):e61176. doi: 10.7759/cureus.61176. eCollection 2024 May. Cureus. 2024. PMID: 38933639 Free PMC article.
Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis.
Mattarucchi E, Spinelli O, Rambaldi A, Pasquali F, Lo Curto F, Campiotti L, Porta G. Mattarucchi E, et al. J Mol Diagn. 2009 Sep;11(5):482-7. doi: 10.2353/jmoldx.2009.080150. J Mol Diagn. 2009. PMID: 19710400 Free PMC article.
Reducing uncertainty in health-care resource allocation.
Simonsson T, Sjölund K, Bümming P, Ahlman H, Nilsson B, Odén A. Simonsson T, et al. Br J Cancer. 2007 Jun 18;96(12):1834-8. doi: 10.1038/sj.bjc.6603795. Epub 2007 May 22. Br J Cancer. 2007. PMID: 17519908 Free PMC article.
Role of NCCN in Integrating Cancer Clinical Practice Guidelines into the Healthcare Debate.
Benson AB 3rd, Brown E. Benson AB 3rd, et al. Am Health Drug Benefits. 2008 Feb;1(1):28-33. Am Health Drug Benefits. 2008. PMID: 25126208 Free PMC article.
Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J. Darkow T, et al. Pharmacoeconomics. 2007;25(6):481-96. doi: 10.2165/00019053-200725060-00004. Pharmacoeconomics. 2007. PMID: 17523753

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information